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Abstract
Preference for the northern (N) ring conformation of the ribose moiety of adenine nucleotide 3′,
5′-bisphosphate antagonists of P2Y1 receptors was established by using a ring-constrained
methanocarba (a bicyclo[3.1.0]hexane) ring as a ribose substitute (Nandanan et al. J. Med. Chem.
2000, 43, 829–842). We have now combined the ring-constrained (N)-methanocarba modification
with other functionalities at the 2-position of the adenine moiety. A new synthetic route to this
series of bisphosphate derivatives was introduced, consisting of phosphorylation of the
pseudoribose moiety prior to coupling with the adenine base. The activity of the newly
synthesized analogues was determined by measuring antagonism of 2-methylthio-ADP-stimulated
phospholipase C (PLC) activity in 1321N1 human astrocytoma cells expressing the recombinant
human P2Y1 receptor and by using the radiolabeled antagonist [3H]2-chloro-N6-methyl-(N)-
methanocarba-2′-deoxyadenosine 3′,5′-bisphosphate 5 in a newly developed binding assay in Sf9
cell membranes. Within the series of 2-halo analogues, the most potent molecule at the hP2Y1
receptor was an (N)-methanocarba N6-methyl-2-iodo analogue 12, which displayed a Ki value in
competition for binding of [3H]5 of 0.79 nM and a KB value of 1.74 nM for inhibition of PLC.
Thus, 12 is the most potent antagonist selective for the P2Y1 receptor yet reported. The 2-iodo
group was substituted with trimethyltin, thus providing a parallel synthetic route for the
introduction of an iodo group in this high-affinity antagonist. The (N)-methanocarba-2-methylthio,
2-methylseleno, 2-hexyl, 2-(1-hexenyl), and 2-(1-hexynyl) analogues bound less well, exhibiting
micromolar affinity at P2Y1 receptors. An enzymatic method of synthesis of the 3′,5′-
bisphosphate from the corresponding 3′-monophosphate, suitable for the preparation of a
radiophosphorylated analogue, was explored.
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Two families of P2 nucleotide receptors exist: G protein-coupled P2Y receptors, of which
eight mammalian subtypes (P2Y1,2,4,6,11–14) are currently sequence-defined, and P2X
ligand-gated cation channels, of which seven mammalian subtypes (P2X1–7) have been
cloned.1–4 Adenine nucleotides are required for activation of the P2Y1, P2Y11, P2Y12, and
P2Y13 subtypes, and uracil nucleotides activate P2Y2, P2Y4, and P2Y6, subtypes. The P2Y2
receptor is equipotently activated by UTP and ATP. The most recently identified subtypes
are the P2Y13 receptor, which is present in the immune system,5 and the P2Y14 receptor,
which is activated by UDP-glucose.6 There is evidence that multiple P2Y receptors may be
involved in the activation of eosinophils and neutrophils.7
The P2Y1 receptor is distributed in the heart, skeletal, and various smooth muscles and the
prostate, ovary, brain, and circulating blood cells.8 This receptor was first cloned from chick
brain;9 its regional brain distribution and presence in glial cells have been described,10–12
and abnormalities in P2Y1 receptor levels may exist in the brains of persons with
Alzheimer’s disease.13 Activation of this receptor by ADP mediates relaxation in the guinea
pig aorta.14 The P2Y1 receptor plays a major physiological role in platelet aggregation.15
P2Y receptor ligands are being explored for therapeutic applications in the cardiovascular,
endocrine, and other systems. The P2Y1 and P2Y12 receptors are the furthest advanced in
the P2Y family with respect to selective agonists and antagonists.16–26 3′,5′-Bisphosphate
nucleotides have been developed as selective antagonists of the P2Y1 receptor, and high
receptor affinities have been achieved in this series.20 The 2′-deoxyribose moiety of widely
used P2Y1 receptor antagonists such as N6-methyl-2′-deoxyadenosine 3′,5′-bisphosphate 1
may be replaced with carbocyclics, smaller and larger rings, acyclics, and conformationally
constrained rings,17–19 resulting in retention or enhancement of affinity for the receptor. A
2-chloro group was found to enhance potency and selectivity in the case of nucleotide 2 and
the acyclic bisphosphate analogue 3.19,27 An acyclic bisphosphonate analogue 4 was also
shown to be a P2Y1 receptor antagonist.19
The most recently introduced P2Y1 receptor antagonists contain novel substitutions of the
ribose moiety or of the adenine ring system. In solution, the conformation of the ribose ring
of nucleosides and nucleotides exists in a rapid, dynamic two-state equilibrium between a
(N) (northern, 2′-exo) or (S) (southern, 2′-endo) conformation, although their target
Kim et al. Page 2













receptors probably prefer specific conformations. We have replaced the ribose moiety for
P2Y1 antagonists with a carbocyclic ring locked in a preferred conformation, a fusion of
cyclopropane and cyclopentane rings known as the methanocarba modification.28–30 Two
structural variations, depending on the position of the cyclopropane ring, restrict the ring
pucker, i.e., hold the riboselike ring (pseudosugar) in either a (N)- or (S)-envelope
conformation, as defined in the pseudorotational cycle. A prototypical ring-constrained
P2Y1 antagonist is the highly potent (N)-methanocarba derivative 2-chloro-N6-methyl-(N)-
methanocarba-2′-deoxyadenosine 3′,5′-bisphosphate 5.18,20 This molecule was also
prepared in [3H]-labeled form and provides the first broadly reliable high-affinity antagonist
for quantitation of a P2Y receptor in a radioligand binding assay.31 The recently reported C-
nucleoside pyrazolo[1,5-a]-1,3,5-triazine bisphosphate 6 is also a potent P2Y1 antagonist.25
In the present study, we combined the ring-constrained (N)-methanocarba modification of
adenine nucleotides with other adenine 2-position functionalities to prepare novel analogues,
which were evaluated for affinity at the human P2Y1 receptor. In one case, a 2-iodo
substitution conferred a significant increase in antagonist potency. New synthetic routes to
antagonists in this series, including methods for introduction of phosphate groups as either
the terminal step or prior to the coupling of sugar and nucleobase, were explored. The 2-iodo
substituent could also be introduced at various stages of the synthesis.
Experimental Section
Chemical Synthesis
Nucleosides and synthetic reagents were purchased from Sigma Chemical Co. (St. Louis,
MO) and Aldrich (Milwaukee, WI). 2,6-Dichloropurine was obtained from Sigma. The
protected intermediate 19 was synthesized in our laboratory as described.45 5 and 9 were
prepared as described.18 37 and 38 were prepared as described.37
1H NMR spectra were obtained with a Varian Gemini-300 spectrometer (300 MHz) with
D2O, CDCl3, CD3OD, and DMSOd6 as a solvent. Tetramethylsilane (TMS) was the external
standard. 31P NMR spectra were recorded at room temperature with a Varian XL-300
spectrometer (121.42 MHz); orthophosphoric acid (85%) was used as an external standard.
Purity of compounds was checked with a Hewlett-Packard 1100 HPLC apparatus equipped
with a Luna 5µ C18(2) analytical column (250 × 4.6 mm, Phenomenex, Torrance, CA) in
two solvent systems.
System A: linear gradient solvent system, 0.1 M TEAA/CH3-CN from 95/5 to 40/60 in 20
min; the flow rate was 1 mL/min.
System B: linear gradient solvent system, 5 mM TBAP/CH3-CN from 80/20 to 40/60 in 20
min; the flow rate was 1 mL/min.
Peaks were detected by UV absorption with a diode array detector. All derivatives tested for
biological activity showed ≥ 97% purity in the HPLC systems.
Low-resolution CI–NH3 (chemical ionization) mass spectra were measured with a Finnigan
4600 mass spectrometer, and high-resolution EI (electron impact) mass spectrometry was
performed with a VG7070F mass spectrometer at 6 kV. High-resolution FAB (fast atom
bombardment) mass spectrometry was performed with a JEOL SX102 spectrometer with 6-
kV Xe atoms following desorption from a glycerol matrix.
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Purification of the nucleotide analogues for biological testing was carried out on Sephadex-
DEAE-A-25 resin columns with a linear gradient (0.01–0.5 M) of 0.5 M ammonium
bicarbonate applied as the mobile phase.
(1′R,2′S,4′S,5′S)-4-(6-Amino-2-iodo-9H-purin-9-yl)-1-[(phosphato)methyl]-2-
(phosphato)bicyclo[3.1.0]-hexane Tetraammonium Salt (7)
Compound 29 (1.48 mg, 0.0023 mmol) was dissolved in 30% NH3 in water (0.50 mL) and
stirred for 6.5 h at 60 °C in a sealed tube. The solvent was removed under reduced pressure.
Purification of the obtained residue was performed on an ion-exchange column packed with
Sephadex-DEAE A-25 resin. A linear gradient (0.01–0.5 M) of 0.5 M ammonium
bicarbonate was applied as the mobile phase, and UV and HPLC were used to monitor the
elution, which furnished 7 (0.77 mg, 54%): 1H NMR (D2O) δ 8.58 (s, 1H), 5.20–4.80 (m,
2H), 4.60–4.40 (m, 1H), 3.60–3.56 (m, 1H), 2.35–2.20 (m, 1H), 2.00–1.88 (m, 1H), 1.88–
1.80 (m, 1H), 1.18–1.12 (m, 1H), 0.99–0.91 (m, 1H); 31P NMR (D2O) δ 0.17, −0.25 (2s, 3′-
P, 5′-P); MS (m/e) (negative-FAB) 546 (M+ − 1); HRMS (negative−FAB) calcd for
C12H15N5O8P2I 545.9441, found 545.9454; HPLC 8.3 min (99%) (system A), 14.3 min
(99%) (system B).
(1′R,2′S,4′S,5′S)-4-(6-Amino-2-methylthio-9H-purin-9-yl)-1-[(phosphato)methyl]-2-
(phosphato)bicyclo[3.1.0]-hexane Tetraammonium Salt (8)
To a solution of 26 (1.70 mg, 0.0020 mmol) in CH2Cl2 (0.30 mL) was added 1.0 M BCl3 in
CH2Cl2 (0.50 mL) and the mixture stirred for 2 d at 5 °C. The reaction was quenched upon
addition of 5.0 mL of triethylammonium bicarbonate buffer (1.0 M). The mixture was
subsequently frozen and lyophilized, which furnished crude 8 (1.90 mg): MS (m/e)
(negative-FAB) 485, 487 (peak height ratio = 3:1) (M+ − 1); HPLC 15.6 min (99%) (system
B).
The crude sample of 8 (1.90 mg) was dissolved in 30% NH3 in water (3.0 mL) and stirred
for 2 h at 70 °C in a sealed tube. The solvent was removed under reduced pressure, the
obtained residue was purified on an ion-exchange column packed with Sephadex-DEAE
A-25 resin, a linear gradient (0.01–0.5 M) of 0.5 M ammonium bicarbonate was applied as
the mobile phase, and UV and HPLC were used to monitor the elution, which furnished
homogeneous 8 (1.90 mg, 94%): 1H NMR (D2O) δ 8.44 (s, 1H), 5.30–5.20 (m, 1H), 5.09 (d,
1H, J = 6.5 Hz), 4.90–4.75 (m, 1H), 3.70–3.55 (m, 1H), 2.60 (s, 3H), 2.30–2.20 (m, 1H),
2.00–1.94 (m, 1H), 1.85–1.80 (m, 1H), 1.17–1.14 (m, 1H), 0.96–0.94 (m, 1H); 31P NMR
(D2O) δ 2.03, 1.36 (2s, 3′-P, 5′-P); MS (m/e) (negative-FAB) 466 (M+ − 1); HRMS
(negative−FAB) calcd for C13H18N5O8P2S 466.0374, found 466.0363; HPLC 8.7 min
(99%) in solvent system A, 14.1 min (99%) in a solvent system B.
(1′R,2′S,4′S,5′S)-4-(2-Fluoro-6-methylamino-9H-purin-9-yl)-1-[(phosphato)methyl]-2-
(phosphato)bicyclo[3.1.0]-hexane Tetraammonium Salt (10)
The mixture of 44 (5 mg, 0.0074 mmol) in 5% TFA/CH2Cl2 (5 mL) was stirred at room
temperature for 3 h. After solvent was removed, the residue was treated with
triethylammonium bicarbonate buffer (1 M, 0.5 mL) and stirred for 30 min. The aqueous
layer was washed twice with CH2Cl2 and evaporated to dryness under reduced pressure. The
residue was purified with ion-exchange column chromatography with the use of Sephadex-
DEAE-A-25 resin with a linear gradient (0.01–0.5 M) of 0.5 M NH4-HCO3 as the mobile
phase. After lyophilization, 10 (1.38 mg, 36%) was obtained as a white solid: 1H NMR
(D2O) δ 8.25 (s, 1H), 5.25–5.1 (m, 2H), 3.8–3.65 (m, 2H), 3.05 (s, 3H), 2.4–2.1 (1H), 2.1–
1.9 (m, 2H), 1.1–0.9 (1H); 31P NMR (D2O) 0.878 (s), 1.2 (s); HRMS (m/e) (negative-FAB)
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calcd forC13H18FN5O8P2 452.0536, found 452.0548; HPLC 8.2 (99%) min in solvent
system A, 16.1 min (99%) in solvent system B.
(1′R,2′S,4′S,5′S)-[4-(2-Bromo-6-methylamino-9H-purin-9-yl)-1-[(phosphato)methyl]-2-
(phosphato)bicyclo[3.1.0]-hexane Tetraammonium Salt (11)
The mixture of 45 (3.0 mg, 0.0041 mmol) in 5% TFA/CH2Cl2 (5 mL) was stirred at room
temperature for 3 h. After removal of the solvent, the residue was treated with
triethylammonium bicarbonate buffer (1 M, 0.5 mL) and stirred for 30 min. The aqueous
layer was washed twice with CH2Cl2 and evaporated to dryness. The residue was purified
with ion-exchange column chromatography with the use of Sephadex-DEAE-A-25 resin
with a linear gradient (0.01–0.5 M) of 0.5 M NH4HCO3 as the mobile phase. After
lyophilization, 11 (1.36 mg, 58%) was obtained as a white solid: 1H NMR (D2O) δ 8.42 (s,
1H), 5.4–5.1 (m, 2H), 3.8–3.6 (m, 2H), 3.1 (s, 3H), 2.4–2.1 (m, 2H), 2.1–1.8 (m, 2H), 1.1–
0.9 (1H); 31P NMR (D2O) δ 0.4 (s), 0.9 (s); HRMS (m/e) (negative-FAB) calcd for
C13H18BrN5O8P2 511.9736, found 511.9763; HPLC 9.3 min (99%) in solvent system A,
14.5 min (99%) in solvent system B.
(1′R,2′S,4′S,5′S)-4-(2-Iodo-6-methylaminopurin-9-yl)-1-[(phosphato)methyl]-2-
(phosphato)bicyclo[3.1.0]-hexane (12)
Method A—Compound 29 (3.61 mg, 0.0057 mmol) was dissolved in 40% MeNH2 in water
(2.0 mL) and stirred for 26 h at room temperature. The solvent was removed under reduced
pressure. Purification of the obtained residue was performed on an ion-exchange column
packed with Sephadex-DEAE A-25 resin, a linear gradient (0.01–0.5 M) of 0.5 M
ammonium bicarbonate was applied as the mobile phase, and UV and HPLC were used to
monitor the elution, which furnished 12 (0.73 mg, 20%).
Method B—A solution of the 2-iodo bis(di-tert-butyl phosphate) derivative 46 (7.1 mg,
9.03 µmol) in 5% trifluoroacetic acid in methylene chloride was stirred for 2 h at room
temperature. All volatile material was removed in vacuo. The residue was purified by using
ion-exchange column chromatography on Sephadex-DEAE-25 resin and a linear gradient
(0–0.5 M) of 0.5 M ammonium bicarbonate as the mobile phase to give the 2-iodo
bisphosphate derivative 12 (2.9 mg, 55%) as an ammonium salt: 1H NMR (D2O) δ 8.54 (bs,
1H), 5.19 (m, 1H), 5.01 (d, 1H, J = 6.9 Hz), 4.58 (dd, 1H, J = 4.7, 11.3 Hz), 3.73 (dd, 1H, J
= 4.4, 11.0 Hz), 3.07 (bs, 3H), 2.28 (dd, 1H, J = 7.7, 14.6 Hz), 1.92–2.09 (m, 2H), 1.26 (dd,
1H, J = 4.1, 6.1 Hz), 1.06 (dd, 1H, J = 9.7, 16.3 Hz); 31P NMR (D2O) 0.651 (s); HRMS
(negative-ion FAB) calcd for C13H17N5O8P2I 559.9597, found 559.9604; HPLC 9.8 min
(97%) in solvent system A, 15.4 min (97%) in system B.
(1′R,2′S,4′S,5′S)-4-(6-Methylamino-2-methylthio-9H-purin-9-yl)-1-[(phosphato)methyl]-2-
(phosphato)bicyclo-[3.1.0]hexane Tetraammonium Salt (13)
To a solution of 28 (4.2 mg, 0.0050 mmol) in CH2Cl2 (0.30 mL) was added 1.0 M BCl3 in
CH2Cl2 (0.60 mL) and the mixture stirred for 2 d at 5 °C. The reaction was quenched upon
the addition of 5.0 mL of triethylammonium bicarbonate buffer (1.0 M). The mixture was
subsequently frozen and lyophilized.
Purification of the obtained residue was performed on an ion-exchange column packed with
Sephadex-DEAE A-25 resin, a linear gradient (0.01–0.5 M) of 0.5 M ammonium
bicarbonate was applied as the mobile phase, and UV and HPLC were used to monitor the
elution, which furnished 13 (1.69 mg, 81%): 1H NMR (D2O) δ 8.45 (s, 1H), 5.25–5.15 (m,
1H), 5.08–5.02 (m, 1H), 4.65–4.60 (m, 1H), 3.65–3.55 (m, 1H), 3.13 (bs, 3H), 2.62 (s, 3H),
2.30–2.20 (m, 1H), 2.00–1.85 (m, 1H), 1.85–1.75 (m, 1H), 1.15–1.10 (m, 1H), 1.00–0.95
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(m, 1H); 31P NMR (D2O) δ 2.21, 2.90 (2s, 3′-P, 5′-P); MS (m/e) (negative-FAB) 480 (M+
− 1); HRMS (negative–FAB) calcd for C14H20N5O8P2S 480.0488, found 480.0498; HPLC
10.3 min (99%) in solvent system A, 16.4 min (99%) in solvent system B.
(1′R,2′S,4′S,5′S)-4-(6-Methylamino-2-methylselenopurin-9-yl)-1-[(phosphato)methyl]-2-
(phosphato)bicyclo-[3.1.0]hexane Tetraammonium Salt (14)
Compound 30 (0.38 mg, 0.63 µmol) was dissolved in 40% MeNH2 in water (3.0 mL) and
stirred for 8 h at 80 °C. The solvent was removed under reduced pressure. Purification of the
obtained residue was performed on an ion-exchange column packed with Sephadex-DEAE
A-25 resin, a linear gradient (0.01–0.5 M) of 0.5 M ammonium bicarbonate was applied as
the mobile phase, and UV and HPLC were used to monitor the elution, which furnished 14
(0.30 mg, 79%): 1H NMR (D2O) δ 8.51 (s, 1H), 5.10–5.00 (m, 1H), 5.00–4.90 (m, 1H),
4.74–4.72 (m, 1H), 3.65–3.50 (m, 1H), 3.14 (bs, 3H), 2.53 (s, 3H), 2.40–2.18 (m, 1H), 2.05–
1.85 (m, 1H), 1.85–1.75 (m, 1H), 1.25–1.14 (m, 1H), 1.00–0.95 (m, 1H); 31P NMR (D2O) δ
3.00, 3.53 (2s, 3′-P, 5′-P); MS (m/e) (negative-FAB) 528 (M+ − 1), HRMS (negative–FAB)
calcd for C14H20N5O8P2Se 527.9948, found 527.9950; HPLC 10.8 min (99%) in solvent
system A, 16.8 min (99%) in solvent system B.
(1′R,2′S,4′S,5′S)-Phosphoric Acid [4-(2-Methyl-6-methylaminopurin-9-yl)-1-
phosphonooxymethylbicyclo[3.1.0]-hex-2-yl] Monoester (15)
A solution of 47 (8.0 mg, 0.012 mmol) in 5% TFA/CH2Cl2 (2.0 mL) was stirred for 3 h at
25 °C. The solvent was removed under reduced pressure and the residue was quenched by
addition of 5.0 mL of triethylammonium bicarbonate buffer (1.0 M). The mixture was
subsequently frozen and lyophilized. Purification of the obtained residue was performed on
an ion-exchange column packed with Sephadex-DEAE A-25 resin, a linear gradient (0.01–
0.5 M) of 0.5 M ammonium bicarbonate was applied as the mobile phase, and UV and
HPLC were used to monitor the elution, which furnished 15 (4.5 mg, 73%): 1H NMR (D2O)
δ 8.45 (s, 1H), 5.18 (m, 1H), 5.00 (d, 1H, J = 5.4 Hz), 4.57–4.50 (m, 1H), 3.69–3.62 (m,
1H), 3.13 (s, 3H), 2.53 (s, 3H), 2.30–2.20 (m, 1H), 2.24–1.92 (m, 1H), 1.88 (m, 1H), 1.19
(m, 1H), 0.98 (m, 1H); 31P NMR (D2O) δ 1.05, 0.65 (2s, 3′-P, 5′-P); MS (m/e) (negative-
FAB) 448 (M+ − 1); HRMS (negative-FAB) calcd for C14H20N5O8P2 448.0787, found
448.0807; HPLC 7.3 min (99%) (system A), 14.2 min (99%) (system B).
(1′R,2′S,4′S,5′S)-4-(2-Hexyl-6-methylaminopurin-9-yl)-1-[(phosphato)methyl]-2-
(phosphato)bicyclo[3.1.0]-hexane (16)
The 2-hexanyl bisphosphate derivative 16 (5.6 mg, 69%) was prepared by the same method
as above for 11, except the 2-hexanyl bis(di-tert-butyl phosphate) derivative 48 (11.2 mg,
0.015 mmol) was used as the starting material: 1H NMR (D2O) δ 8.54 (bs, 1H), 5.23 (m,
1H), 5.10 (d, 1H, J = 6.6 Hz), 4.57 (dd, 1H, J = 5.2, 11.3 Hz), 3.70 (m, 1H), 3.25 (bs, 3H),
2.85 (dd, 2H, J = 7.4, 7.7 Hz), 2.29 (dd, 1H, J = 7.7, 15.1 Hz), 2.03 (dt, 1H, J = 6.6, 16.8
Hz), 1.92 (dd, 1H, J = 3.8, 9.1 Hz), 1.773 (m, 2H), 1.13–1.43 (m, 9H), 1.03 (dd, 1H, J = 6.6,
7.7 Hz), 0.85 (m, 3H); 31P NMR (D2O) 0.827 (s), 0.375 (s); HRMS (negative-ion FAB)
calcd for C19H30N5O8P2 518.1570, found 518.1544; HPLC 13.2 min (98%) in solvent
system A, 16.6 min (97%) in system B.
(1′R,2′S,4′S,5′S)-4-(2-Hex-1-ynyl-6-methylaminopurin-9-yl)-1-[(phosphato)methyl]-2-
(phosphato)bicyclo[3.1.0]-hexane (17)
The 2-hexenyl bisphosphate derivative 17 (3.2 mg, 68%) was prepared by the same method
as above for 11, except the 2-hexenyl bis(di-tert-butyl phosphate) derivative 49 (6.0 mg,
8.08 µmol) was used as the starting material: 1H NMR (D2O) δ 8.54 (s, 1H), 7.18 (dt, 1H, J
= 7.1, 15.4 Hz), 6.45 (m, 1H), 5.22 (m, 1H), 5.08 (d, 1H, J = 6.3 Hz), 4.57 (dd, 1H, J = 4.7,
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11.0 Hz), 3.71 (dd, 1H, J = 5.0, 10.7 Hz), 3.22 (bs, 3H), 2.23–2.44 (m, 3H), 2.03 (m, 1H),
1.95 (dd, 1H, J = 3.7, 8.8 Hz), 1.32–1.61 (m, 4H), 1.24 (dd, 1H, J = 4.1, 5.5 Hz), 1.05 (dd,
1H, J = 6.3, 8.2 Hz), 0.94 (m, 3H); 31P NMR (D2O) 0.601 (s), 0.299 (s); HRMS (negative-
ion FAB) calcd for C19H28N5O8P2 516.1413, found 516.1403; HPLC 13.5 min (99%) in
solvent system A, 16.9 min (99%) in solvent system B.
(1′R,2′S,4′S,5′S)-4-(2-Hex-1-enyl-6-methylaminopurin-9-yl)-1-[(phosphato)methyl]-2-
(phosphato)bicyclo[3.1.0]-hexane (18)
The 2-hexynyl bisphosphate derivative 18 (4.0 mg, 73%) was prepared by the same method
as above for 11, except the 2-hexynyl bis(di-tert-butyl phosphate) derivative 50 (7.0 mg,
9.46 µmol) was used as the starting material: 1H NMR (D2O) δ 8.46 (s, 1H), 5.16 (m, 1H),
4.97 (d, 1H, J = 6.3 Hz), 4.56 (dd, 1H, J = 4.7, 11.3 Hz), 3.70 (dd, 1H, J = 6.3, 11.3 Hz),
3.07 (bs, 3H), 2.50 (t, 2H, J = 7.1 Hz), 2.24 (dd, 1H, J = 7.4, 14.6 Hz), 1.91–2.05 (m, 2H),
1.42–1.71 (m, 4H), 1.23 (dd, 1H, J = 4.1, 5.8 Hz), 1.03 (dd, 1H, J = 6.1, 8.2 Hz), 0.95 (t, 3H,
J = 7.2 Hz); 31P NMR (D2O) 0.777 (s), 0.375 (s); HRMS (negative-ion FAB) calcd for
C19H26N5O8P2 514.1257, found 514.1234; HPLC 12.4 min (98%) in solvent system A, 12.3
min (99%) in solvent system B.
General (Phosphorylation) Procedure: Synthesis of (N)-Methanocarbaadenosine
Derivatives (21–57). (1′R,2′S,-4′S,5′S)-4-(2-Amino-6-chloro-9H-purin-9-yl)-1-
(benzyloxymethyl)-2-benzyloxybicyclo[3.1.0]hexane (21)
To a solution of triphenylphosphine (0.20 g, 0.76 mmol) in anhydrous tetrehydrofuran
(THF, 1.0 mL) was added dropwise diisopropyl azodicarboxylate (DIAD, 0.15 mL, 0.76
mmol) at −20 °C with stirring for 0.5 h. Compound 19 (76 mg, 0.23 mmol) and 2-amino-6-
chloropurine 20 (92 mg, 0.54 mmol) in THF (5.0 mL) were added to the reaction mixture
and it stirred for 18.5 h at room temperature. The solvent was removed under vacuum, and
the residue obtained was purified by using flash chromatography with 1/1 petroleum ether/
ethyl acetate to furnish 21 (103 mg, 92%): 1H NMR (CDCl3) δ 8.58 (s, 1H), 7.40–7.21 (m,
10H), 5.01 (bs, 1H), 4.97 (d, 1H, J = 6.6 Hz), 4.66 (t, 1H, J = 8.25 Hz), 4.54 (s, 2H), 4.45 (d,
1H, J = 11.7 Hz), 4.38 (d, 1H, J = 11.7 Hz), 4.09 (d, 1H, J = 9.8 Hz), 3.14 (d, 1H, J = 9.8
Hz), 2.09–2.00 (m, 1H), 1.85–1.74 (m, 1H), 1.59–1.54 (m, 1H), 1.11–1.06 (m, 1H), 0.81–
0.75 (m, 1H); MS (m/e) (positive-FAB) 476, 478 (peak height ratio = 3:1) (M+ + 1).
(1′R,2′S,4′S,5′S)-4-(2-Amino-6-chloro-9H-purin-9-yl)-1-(hydroxymethyl)-2-
hydroxybicyclo[3.1.0]hexane (22)
Compound 21 (169 mg, 0.353 mmol) was dissolved in CH2Cl2 (5.0 mL) and treated with
BCl3 (1 M in CH2Cl2, 1.50 mL) for 1 h at −40 °C under argon. i-PrOH (0.40 mL) was added
to the reaction mixture and it was warmed to room temperature. The solvent was evaporated,
and the crude product was purified by flash column chromatography with AcOEt/i-PrOH
(1/1) to yield 22 as a white solid (72 mg, 69%): 1H NMR (CD3OD) δ 8.54 (s, 1H), 4.94 (d,
1H, J = 6.6 Hz), 4.26 (d, 1H, J = 11.7 Hz), 4.03 (s, 1H), 3.33 (d, 1H, J = 11.7 Hz), 2.09–1.98
(m, 1H), 1.84–1.73 (m, 1H), 1.67–1.62 (m, 1H), 1.04–0.99 (m, 1H), 0.79–0.74 (m, 1H); MS
(m/e) (negative-FAB) 294, 296 (peak height ratio = 3:1) (M+ − 1).
(1′R,2′S,4′S,5′S)-4-(2-Amino-6-chloro-9H-purin-9-yl)-1-[(dibenzylphosphato)methyl]-2-
(dibenzylphosphato)-bicyclo[3.1.0]hexane (24)
To a stirred solution of 22 (56 mg, 0.190 mmol) and 1H-tetrazole (130 mg, 1.86 mmol) in
3.0 mL of anhydrous THF was added dibenzyl diisopropylphosphoramidite (23, 0.30 mL,
0.89 mmol), and the mixture was stirred for 4.5 h at room temperature. The reaction mixture
was cooled to −78 °C and treated with a solution of m-chloroperbenzoic acid (m-CPBA,
70% max, 350 mg) in CH2Cl2 (5.0 mL). The resulting mixture was warmed to room
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temperature, and the solvent was removed under reduced pressure. The residue obtained was
purified by flash column chromatography (1/1 = AcOEt/CH2Cl2), which furnished 24 (52
mg, 35%): 1H NMR (CDCl3) δ 7.82 (s, 1H), 7.33–7.25 (m, 20H), 5.41 (dd, 1H, J = 7.8, 14.1
Hz), 5.27 (bs, 2H), 5.05–4.91 (m, 8H), 4.74 (d, 1H, J = 6.9 Hz), 4.54 (dd, 1H, J = 5.7, 11.1
Hz), 3.94 (dd, 1H, J = 6.0, 11.1 Hz), 2.14–2.04 (m, 1H), 1.98–1.87 (m, 1H), 1.62–1.52 (m,
1H), 1.00–0.93 (m, 1H), 0.87–0.80 (m, 1H); MS (m/e) (positive-FAB) 816, 818 (peak height
ratio = 3:1) (M+ + 1).
(1′R,2′S,4′S,5′S)-4-(6-Chloro-2-iodo-9H-purin-9-yl)-1-[(dibenzylphosphato)methyl]-2-
(dibenzylphosphato)-bicyclo[3.1.0]hexane (25)
To a solution of 24 (62.1 mg, 0.0761 mmol) in acetonitrile (0.50 mL) were added
diiodomethane (2.0 mL) and tert-butyl nitrite (0.10 mL, 1.11 mmol) were added, and oxygen
was purged by N2 bubbling. The tube was sealed and stirred at 85 °C for 3.0 h.
Diiodomethane was removed upon passage though a short column (silica gel, eluting with
CHCl3, then AcOEt). The residue obtained was purified by preparative thin-layer
chromatography (AcOEt), which furnished 25 (25.8 mg, 37%): 1H NMR (CDCl3) δ 8.19 (s,
1H), 7.36–7.25 (m, 20H), 5.29 (q, 1H, J = 6.9 Hz), 5.10–4.92 (m, 9H), 4.61 (dd, 1H, J = 6.3,
12.0 Hz), 3.84 (dd, 1H, J = 6.6, 12.0 Hz), 2.05–1.88 (m, 2H), 1.62–1.52 (m, 1H), 1.02 (m,




To a solution of 24 (4.5 mg, 0.0056 mmol) in MeCN (0.25 mL) were added dimethyl
disulfide (0.15 mL, 1.26 mmol) and tert-butylnitrite (0.050 mL, 0.56 mmol), and oxygen
was purged by nitrogen bubbling. The tube was sealed and stirred at 70 °C for 5.5 h. The
solvent was removed under reduced pressure. The residue obtained was purified by
preparative thin-layer chromatography (2/1=AcOEt/CH2Cl2), which furnished 26 (3.0 mg,
64%): 1H NMR (CDCl3) δ 8.15 (s, 1H), 7.33–7.25 (m, 20H), 5.30 (dd, 1H, J = 7.8, 14.7
Hz), 5.07–4.91 (m, 9H), 4.62 (dd, 1H, J = 6.0, 11.5 Hz), 3.74 (dd, 1H, J = 6.6, 11.5 Hz), 2.61
(s, 3H), 2.14–2.04 (m, 1H), 1.98–1.87 (m, 1H), 1.63–1.56 (m, 1H), 1.07–1.03 (m, 1H), 0.88–
0.81 (m, 1H); MS (m/e) (positive-FAB) 847, 849 (peak height ratio = 3:1) (M+ + 1).
(1′R,2′S,4′S,5′S)-4-(6-Chloro-2-methylseleno-9H-purin-9-yl)-1-
[(dibenzylphosphato)methyl]-2-(dibenzylphosphato)bicyclo[3.1.0]hexane (27)
To a solution of 24 (16.0 mg, 0.0196 mmol) in MeCN (0.30 mL) were added
dimethyldiselenide (0.10 mL, 1.06 mmol) and tert-butyl nitrite (0.100 mL, 1.11 mmol), and
oxygen was purged by nitrogen bubbling. The tube was sealed and stirred at 65 °C for 20 h.
The solvent was removed under reduced pressure. The residue obtained was purified by
preparative thin-layer chromatography (1/1 = AcOEt/CH2Cl2), which furnished 27 (6.7 mg,
38%): 1H NMR (CDCl3) δ 8.16 (s, 1H), 7.40–7.25 (m, 20H), 5.28 (dd, 1H, J = 8.4, 14.4
Hz), 5.10–4.90 (m, 9H), 4.62 (dd, 1H, J = 6.0, 11.4 Hz), 3.74 (dd, 1H, J = 6.6, 14.4 Hz), 2.53
(s, 3H), 2.15–2.00 (m, 1H), 2.00–1.85 (m, 1H), 1.75–1.65 (m, 1H), 1.45–1.35 (m, 1H), 1.10–
1.00 (m, 1H); MS (m/e) (positive-FAB) 895, 897 (peak height ratio = 3:1) (M+ + 1).
(1′R,2′S,4′S,5′S)-4-(6-Methylamino-2-methylthio-9H-purin-9-yl)-1-[(dibenzylphosphato)-
methyl]-2-(dibenzylphosphato)bicyclo[3.1.0]hexane (28)
Compound 26 (3.0 mg, 0.0035 mmol) was dissolved in 2.0 M MeNH2 in THF (0.50 mL)
and stirred for 2.5 h at room temperature. The solvent was removed under reduced pressure.
The residue obtained was purified by preparative thin-layer chromatography (AcOEt), which
furnished 28 (2.7 mg, 91%): 1H NMR (CDCl3) δ 7.77 (s, 1H), 7.30–7.25 (m, 20H), 5.72 (bs,
Kim et al. Page 8













1H), 5.38 (dd, 1H, J = 7.5, 14.1 Hz), 5.03–4.91 (m, 9H), 4.59 (dd, 1H, J = 6.3, 11.4 Hz),
3.78 (dd, 1H, J = 5.1, 11.4 Hz), 3.19 (bs, 3H), 2.57 (s, 3H), 2.19–2.10 (m, 1H), 1.96–1.82
(m, 1H), 1.60–1.55 (m, 1H), 1.04–1.00 (m, 1H), 0.88–0.78 (m, 1H); MS (m/e) (positive-
FAB) 842 (M+ + 1).
(1′R,2′S,4′S,5′S)-4-(6-Chloro-2-iodo-9H-purin-9-yl)-1-[(phosphato)methyl]-2-
(phosphato)bicyclo[3.1.0]-hexane Tetraammonium Salt (29)
To a solution of 25 (13.6 mg, 0.015 mmol) in CH2Cl2 (0.80 mL) was added 1.0 M BCl3 in
CH2Cl2 (0.80 mL) and the mixture stirred for 24 h at 5 °C. The reaction was quenched upon
addition of 3.0 mL of triethylammonium bicarbonate buffer (1.0 M). The mixture was
subsequently frozen and lyophilized. Purification of the residue obtained was performed on
an ion-exchange column packed with Sephadex-DEAE A-25 resin. A linear gradient (0.01–
0.5 M) of 0.5 M ammonium bicarbonate was applied as the mobile phase, and UV and
HPLC were used to monitor the elution, which furnished 29 (5.56 mg, 60%): 1H NMR
(D2O) δ 8.83 (s, 1H), 5.30–5.20 (m, 1H), 5.16 (d, 1H, J = 6.3 Hz), 4.60–4.50 (m, 1H), 3.75–
3.65 (m, 1H), 2.40–2.20 (m, 1H), 2.10–1.95 (m, 1H), 1.95–1.90 (m, 1H), 1.25–1.20 (m, 1H),
1.05–1.00 (m, 1H); 31P NMR (D2O) δ 2.02, 1.40 (2s, 3′-P, 5′-P); MS (m/e) (negative-FAB)
565, 567 (peak height ratio = 3:1) (M+ − 1); HPLC 9.8 min (98%) in solvent system A, 16.0
min (98%) in solvent system B.
(1′R,2′S,4′S,5′S)-4-(6-Chloro-2-methylseleno-9H-purin-9-yl)-1-[(phosphato)methyl]-2-
(phosphato)bicyclo[3.1.0]-hexane Tetraammonium Salt (30)
To a solution of 27 (6.7 mg, 0.0075 mmol) in CH2Cl2 (0.50 mL) was added 1.0 M BCl3 in
CH2Cl2 (0.80 mL) and the mixture stirred for 2 d at 5 °C. The reaction was quenched upon
addition of 5.0 mL of triethylammonium bicarbonate buffer (1.0 M). The mixture was
subsequently frozen and lyophilized. Purification of the obtained residue was performed on
an ion-exchange column packed with Sephadex-DEAE A-25 resin, a linear gradient (0.01–
0.5 M) of 0.5 M ammonium bicarbonate was applied as the mobile phase, and UV and
HPLC were used to monitor the elution, which furnished 30 (1.28 mg, 28%): 1H NMR
(D2O) δ 8.78 (s, 1H), 5.35–5.22 (m, 2H), 4.60–4.50 (m, 1H), 3.70–3.65 (m, 1H), 2.61 (s,
3H), 2.45–2.30 (m, 1H), 2.15–1.95 (m, 1H), 1.95–1.85 (m, 1H), 1.25–1.18 (m, 1H), 1.05–
0.95 (m, 1H); 31P NMR (D2O) δ 1.67, 1.09 (2s, 3′-P, 5′-P); MS (m/e) (negative-FAB) 533,
535 (peak height ratio = 3:1) (M+ − 1), HRMS (negative–FAB) calcd for C13H16N4O8P2Se
532.9293, found 532.9295; HPLC 11.0 min (99%) in solvent system A, 15.5 min (99%) in
solvent system B.
(1′R,2′S,4′R,5′S)-Acetic Acid 4-Hydroxy-5-hydroxymethylbicyclo[3.1.0]hex-2-yl Ester (32)
A mixture of dibenzyl alcohol 19 (137 mg, 0.422 mmol), acetic anhydride (140.4 mg, 1.38
mmol), triethylamine (436 mg, 4.3 mmol), 4-(dimethylamino)pyridine (10 mg, 0.2 mmol),
and dichloromethane (5 mL) was stirred at room temperature for 4 h. The resulting mixture
was partitioned between ethyl acetate (50 mL) and water/brine (1/1, 20 mL). The organic
layer was washed with saturated aqueous sodium bicarbonate (10 mL) and brine (10 mL),
dried over sodium sulfate, filtered, and concentrated in vacuo. The residue was used in the
next reaction without further purification. The dibenzyl acetate 31 (crude 164 mg) was
dissolved in methanol (5 mL). Five percent Pd/C (150 mg) was added. The reaction flask
was applied to a vacuum and filled with hydrogen several times. The reaction mixture was
stirred for 4 h at room temperature under a hydrogen balloon. The resulting mixture was
filtrated through a pad of Celite and washed with methanol (10 mL × 3). The residue was
purified by flash column chromatography (chloroform/methanol = 10/1) to give a diol 32
(76 mg, 97% for two steps yield): 1H NMR (CDCl3) δ 5.13 (m, 1H), 4.45 (t, 1H, J = 8.2
Hz), 3.96 (d, 1H, J = 11.8 Hz), 3.24 (d, 1H, J = 11.8 Hz), 2.33 (dt, 1H, J = 8.0, 13.2 Hz),
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2.01 (s, 3H), 1.66 (m, 1H), 1.27 (dt, 1H, J = 8.8, 13.5 Hz), 1.09 (dd, 1H, J = 3.8, 5.5 Hz),
0.55 (dd, 1H, J = 5.5, 8.0 Hz).
(1′R,2′S,4′R,5′S)-Acetic Acid 4-(Di-tert-butoxyphosphoryloxy)-5-(di-tert-
butoxyphosphoryloxymethyl)-bicyclo[3.1.0]hex-2-yl Ester (33)
To a stirred suspension of diol 32 (25 mg, 0.134 mmol) and diethyl di-tert-
butylphosphoramidite (100.5 mg, 0.402 mmol) in anhydrous tetrahydrofuran (4 mL) at room
temperature was added solid tetrazole (94 mg, 1.34 mmol) in one pot. The reaction mixture
was stirred at room temperature for 1 h and then cooled to −78 °C. To this cooled reaction
mixture was added solid m-CPBA (57–85%, calculated by 57%, 240 mg), and the resulting
mixture was stirred at −78 °C for 20 min and at room temperature for 10 min. After removal
of tetrahydrofuran in vacuo, the residue was directly purified by flash column
chromatography (CHCl3/MeOH = 10/1) to give 33 (71 mg, 93%): 1H NMR (CDCl3) δ 4.87
(dd, 1H, J = 8.0, 14.6 Hz), 4.41 (m, 1H), 4.40 (dd, 1H, J = 7.7, 11.0 Hz), 3.69 (dd, 1H, J =
6.9, 11.0 Hz), 2.46 (dt, 1H, J = 7.7, 13.5 Hz), 1.78 (m, 1H), 1.485 (s, 9H), 1.478 (s, 9H),
1.469 (s, 9H), 1.457 (s, 9H), 1.39 (m, 1H), 1.25 (dd, 1H, J = 5.0, 5.2 Hz), 0.67 (dd, 1H, J =
6.3, 7.4 Hz).
(1′R,2′S,4′R,5′S)-Phosphoric Acid Di-tert-butyl Ester 1-(Di-tert-
butoxyphosphoryloxymethyl)-4-hydroxybicyclo[3.1.0]hex-2-yl Ester (34)
Acetate 33 (70 mg, 0.122 mmol) was dissolved in methanol (3 mL), and then solid
potassium carbonate (20 mg, 0.145 mmol) was added. After the reaction mixture was stirred
for 2 h, methanol was removed in vacuo and the residue was purified by flash column
chromatography (CHCl3/MeOH = 30/1) to produce the bisphosphate alcohol 34 (51 mg,
79%): 1H NMR (CDCl3) δ 5.13 (m, 1H), 4.45 (t, 1H, J = 8.2 Hz), 3.96 (d, 1H, J = 11.8 Hz),
3.24 (d, 1H, J = 11.8 Hz), 2.33 (dt, 1H, J = 8.0, 13.2 Hz), 2.01 (s, 3H), 1.66 (m, 1H), 1.27
(dt, 1H, J = 8.8, 13.5 Hz), 1.09 (dd, 1H, J = 3.8, 5.5 Hz), 0.55 (dd, 1H, J = 5.5, 8.0 Hz); MS
(m/e) (positive-FAB) 529.35 (M+ + 1), 551.31 (M+ + Na + 1).
2-Bromo-6-chloro-9H-purine (35)
To a stirred solution of 20 (0.35 g, 2 mmol) in CH2Br2 (5 mL) was added a solution of
SbBr3 in CH2Br2 (5 mL) at −10 °C. This solution was stirred at this temperature for 10 min,
and tert-butyl nitrite (4.5 mL) was added. The reaction mixture was stirred for 2.5 h at −10
°C and then was poured into a stirred mixture of 2.4 g of NaHCO3 in 100 mL of water and
crushed ice. This mixture was filtered, and the filtrate was extracted with CHCl3 and dried
over Na2SO4. After removal of the solvent, the residue was purified by flash
chromatography (MeOH/CHCl3 = 1/10) to provide 35 (0.404 g, 87%): 1H NMR (DMSO-d6)
δ 8.72 (s, 1H); MS (m/e) (positive-FAB) 233 (M+ + H).
6-Chloro-2-fluoro-9H-purine (36)
Compound 20 (100 mg, 0.572 mmol) was added to 60% HF–pyridine (which was prepared
from 1.5 g of 70% HF–pyridine diluted with 0.25 g of pyridine) at −50 °C with stirring. The
temperature was allowed to rise from −30 °C, and 0.1 mL of tert-butyl nitrite (0.1 mL) was
added dropwise. Stirring was continued for 10 min, and the reaction mixture was poured
into ice water. The aqueous layer was extracted with CHCl3 and ethyl acetate. The
combined organic layer was washed with H2O, dried over Na2SO4, and filtered, and the
filtrate was evaporated. The given residue was purified on a flash column chromatography
(MeOH/CHCl3 = 1/10) to give 36 (90 mg, 91%) as a white solid: 1H NMR (CD3OD) δ 8.5
(s, 1H); MS (m/e) (positive-FAB) 173 (M+ + H).
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The mixture of 36 (56 mg, 0.324 mmol) in CH3NH2 (2.0 M in THF, 3 mL) was stirred at
room temperature overnight. After removal of the solvent, the residue was purified by
preparative thin-layer chromatography (MeOH/CHCl3 = 1/10) to yield 37 (43 mg, 80%): 1H
NMR (DMSO-d6) δ 8.12 (br, 1H), 8.06 (s, 1H), 3.30 (s, 1H), 2.91 (s, 3H); MS (m/e)
(positive-FAB) 168 (M+ + H).
2-Bromo-6-methylamino-9H-purine (38)
The mixture of 35 (130 mg, 0.557 mmol) in CH3NH2 (40% in H2O, 2 mL) was heated to 70
°C and stirred at this temperature for 6 h. The reaction mixture was cooled to room
temperature, and the formed white precipitate was filtered and washed with a small amount
of water/MeOH. The precipitate was dried in a vacuum to give 38 (118 mg, 93%): 1H NMR
(DMSO-d6) δ 8.08 (s, 1H), 8.06 (bs, 1H), 3.30 (s, 1H), 2.91 (s, 3H); MS (m/e) (positive-
FAB) 228 (M+ + H).
(1′R,2′S,4′S,5′S)-4-(2-Fluoro-6-methylamino-9H-purin-9-yl)-1-(di-tert-
butoxyphosphoryloxymethyl)bicyclo[3.1.0]-hex-2-yl-phosphoric Acid Di-tert-butyl Ester
(44)
To an ice-cold solution of triphenylphosphine (23.6 mg, 0.09 mmol) in dry THF (0.5 mL)
was added DIAD (18.7 µL, 0.09 mmol) dropwise under a nitrogen atmosphere, and the
mixture was stirred for 20 min until the solution turned red. This mixture was added
dropwise to a cold, stirred mixture of 34 (14.4 mg, 0.027 mmol) and 37 (15.03 mg, 0.09
mmol) under a nitrogen atmosphere. The reaction mixture was stirred in an ice bath for 30
min and then allowed to warm to room temperature, and stirring continued for 12 h. Solvent
was removed by nitrogen purge, and the residue was purified by preparative thin-layer
chromatography (MeOH/CHCl3 = 1/20) to produce 44 (8.61 mg, 47%) as a thick liquid: 1H
NMR (CDCl3) δ 8.08 (s, 1H), 6.18 (br, 1H), 5.45–5.25 (m, 1H), 5.10–4.9 (m, 1H), 4.75–
4.55 (m, 1H), 4.0–3.8 (m, 1H), 3.17 (s, 3H), 2.45–2.2 (m, 1H), 2.14–1.95 (m, 1H), 1.86–1.75
(m, 1H), 1.49 (s, 18H), 1.47 (s, 18H), 1.2–1.05 (m, 1H), 1.05–0.9 (m, 1H); MS (m/e)
(positive-FAB) 678 (M+ + H).
(1′R,2′S,4′S,5′S)-4-(2-Bromo-6-methylamino-9H-purin-9-yl)-1-(di-tert-
butoxyphosphoryloxymethyl)bicyclo[3.1.0]-hex-2-yl-phosphoric Acid Di-tert-butyl Ester
(45)
To a solution of triphenylphosphine (15 mg, 0.057 mmol) in anhydrous THF (0.5 mL) was
added DIAD (12 µL, 0.057 mmol) dropwise at 0 °C under a nitrogen atmosphere, and the
mixture was stirred at this temperature for 20 min until the solution turned red. This reaction
mixture was added slowly to a cold stirred solution of alcohol 34 (9.2 mg, 0.0174 mmol) and
38 (13.1 mg, 0.057 mmol) under a nitrogen atmosphere. The reaction mixture was stirred in
an ice bath for 30 min and then allowed to warm to room temperature while stirring
continued for 12 h. Solvent was removed by nitrogen purge, and the residue was purified by
preparative thin-layer chromatography (MeOH/CHCl3 = 1/20) to produce 45 (3.1 mg, 23%)
as a thick liquid: 1H NMR (CDCl3) δ 8.05 (s, 1H), 5.92 (br, 1H), 5.45–5.25 (m, 1H), 5.15–
5.0 (m, 1H), 4.75–4.55 (m, 1H), 3.95–3.80 (m, 1H), 3.18 (s, 3H), 2.4–2.2 (m, 1H), 2.20–2.0
(m, 1H), 1.85–1.7 (m, 1H), 1.58 (s, 18H), 1.49 (s, 18H), 1.2–1.05 (m, 1H), 1.05–0.9 (m,
1H); MS (m/e) (positive-FAB) 738 (M+ + H).
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(1′R,2′S,4′S,5′S)-Phosphoric Acid Di-tert-butyl Ester 1-(Di-tert-
butoxyphosphoryloxymethyl)-4-(2-iodo-6-methylaminopurin-9-yl)bicyclo[3.1.0]hex-2-yl
Ester (46)
The alcohol 34 (10 mg, 0.0189 mmol), triphenylphosphine (20 mg, 0.0756 mmol), and 2-
iodo-6-methylaminopurine 39 (10.4 mg, 0.0378 mmol) were mixed and dried under high
vacuum for ~30 min. The residue was dissolved in anhydrous tetrahydrofuran (1 mL) and
cooled to 0 °C. Diethyl azodicarboxylate (DEAD, 9.9 mg, 0.0567 mmol) was added
dropwise via syringe to this solution. After the solution was stirred for 2 h at room
temperature (the progress of the reaction was monitored by thin-layer chromatography),
tetrahydrofuran was removed in vacuo. The residue was purified by preparative thin-layer
chromatography (CHCl3/MeOH = 20/1) to give the desired 2-iodo bis(di-tert-butyl
phosphate) derivative 46 (7.1 mg, 48%): 1H NMR (CDCl3) δ 7.98 (s, 1H), 5.85 (bs, 1H, –
NH), 5.35 (dd, 1H, J = 7.7, 14.3 Hz), 5.07 (d, 1H, J = 6.9 Hz), 4.66 (dd, 1H, J = 4.7, 11.0
Hz), 3.91 (dd, 1H, J = 6.6, 11.3 Hz), 3.17 (bs, 3H), 2.31 (dd, 1H, J = 8.0, 15.4 Hz), 2.09 (dt,
1H, J = 8.2, 14.8 Hz), 1.76 (dd, 1H, J = 4.4, 8.5 Hz), 1.32 (s, 18H), 1.29 (s, 9H), 1.26 (s,
9H), 1.10 (dd, 1H, J = 4.1, 6.0 Hz), 0.99 (m, 1H); MS (m/e) (positive-FAB) 786.3 (M+ + 1).
2-Amino-6-chloropurin-9-ylmethyl 2,2-Dimethylpropionate (54)
2-Amino-6-chloropurine 20 (1.00 g, 5.90 mmol) was dissolved in DMSO (5.0 mL) under
heating. To this solution were added DMF (20.0 mL), chloromethyl pivalate 53 (1.0 mL,
6.94 mmol), and K2CO3 (990 mg, 7.16 mmol), and the mixture was stirred at room
temperature for 3 days. The reaction mixture was filtered and the filtrate was evaporated.
The obtained residue was purified by flash chromatography (AcOEt/petroleum ether = 2/1)
and recrystallized from AcOEt/petroleum ether, which furnished 54 (1.33 g, 79%): 1H NMR
(CDCl3) δ 8.01 (s, 1H), 6.00 (s, 2H), 5.20 (bs, 2H), 1.18 (s, 9H); MS (m/e) (positive-FAB)
284, 286 (peak height ratio 3:1) (M+ + 1).
6-Chloro-2-iodopurin-9-ylmethyl 2,2-Dimethylpropionate (55)
To a solution of 2-amino-6-chloropurin-9-yl-methyl 2,2-dimethylpropionate 54 (704 mg,
2.48 mmol) in MeCN (2.0 mL) were added diiodomethane (8.0 mL) and tert-butylnitrite
(0.90 mL, 9.99 mmol), and oxygen was purged by N2 bubbling. The tube was sealed and the
contents stirred at 80 °C for 2.5 h. The solvent was removed under vacuum and the obtained
residue was purified by flash chromatography (AcOEt/petroleum ether = 1/2), which
furnished 55 (561 mg, 57%): 1H NMR (CDCl3) 8.29 (s, 1H), 6.14 (s, 2H), 1.19 (s, 9H); MS
(m/e) (positive-FAB) 395, 397 (peak height ratio 3:1) (M+ + 1).
6-Chloro-2-iodopurine (43)
To a solution of 6-chloro-2-iodopurin-9-ylmethyl 2,2-dimethylpropionate 55 (125 mg, 0.317
mmol) in i-PrOH (5.0 mL) and H2O (0.500 mL) was added 5 N aq NaOH (0.200 mL) and
the mixture stirred at room temperature for 3 days. The solvent was removed under reduced
pressure, the residue was poured into saturated aq NaHCO3 and extracted with THF–AcOEt.
The organic layer was washed with brine, dried over Na2SO4, and evaporated. The residue
obtained was purified by flash chromatography (AcOEt), which furnished 43 (42 mg,
48%): 1H NMR (DMSO) δ 8.63 (s, 1H); MS (m/e) (positive-FAB) 281, 283 (peak height
ratio 3:1) (M++1).
(1′R,2′S,4′S,5′S)-Phosphoric Acid Di-tert-butyl Ester 1-(Di-tert-
butoxyphosphoryloxymethyl)-4-(6-chloro-2-iodopurin-9-yl)bicyclo[3.1.0]hex-2-yl Ester (51)
To a solution of triphenylphosphine (70 mg, 0.26 mmol) in anhydrous THF (0.50 mL) was
added DEAD (0.035 mL, 0.22 mmol) dropwise at −20 °C with stirring for 1.0 h. Compound
34 (18 mg, 0.035 mmol) and 6-chloro-2-iodopurine 43 (65 mg, 0.23 mmol) in THF (1.50
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mL) were added to the reaction mixture and it stirred at room temperature for 3 days. The
solvent was removed under vacuum and the residue obtained was purified by preparative
thin-layer chromatography (AcOEt), which furnished 51 (15.5 mg, 57%): 1H NMR (CDCl3)
δ 8.44 (s, 1H), 5.34 (dd, 1H, J = 8.1, 15.0 Hz), 5.16 (d, 1H, J = 6.9 Hz), 4.69 (dd, 1H, J =
5.1, 11.4 Hz), 3.94 (dd, 1H, J = 6.6, 11.4 Hz), 2.40–2.30 (m, 1H), 2.22–2.10 (m, 1H), 1.85–
1.80 (m, 1H), 1.50 (s, 9H), 1.49 (s × 2, 18H), 1.48 (s, 9H), 1.18–1.14 (m, 1H), 1.09–1.03 (m,
1H); MS (m/e) (positive-FAB) 791, 793 (peak height ratio 3:1) (M+ + 1).
(1′R,2′S,4′S,5′S)-Phosphoric Acid Di-tert-butyl Ester 1-(Di-tert-
butoxyphosphoryloxymethyl)-4-(2-iodo-6-methylaminopurin-9-yl)bicyclo[3.1.0]hex-2-yl
Ester (46)
To a solution of 6-chloro-2-methylpurin-9-ylmethyl 2,2-dimethylpropionate 51 (13.0 mg,
0.016 mmol) in THF (0.10 mL) was added 2.0 N MeNH2 in THF (1.0 mL) and the mixture
stirred for 3 h. The solvent was removed under reduced pressure and the obtained residue
was purified by flash chromatography (CHCl3/MeOH = 5/1), which furnished 46 (6.1 mg,
47%).
6-Chloro-2-trimethylstannylpurin-9-ylmethyl 2,2-Dimethylpropionate (56)
To a solution of 6-chloro-2-iodopurin-9-ylmethyl 2,2-dimethylpropionate 55 (323 mg, 0.819
mmol) and PdCl2(PPh3)2 (30 mg, 0.043 mmol) in dioxane (0.75 mL) was added
Me3SnSnMe3 (820 mg, 2.50 mmol) in dioxane (2.0 mL) and the mixture stirred at 100 °C
for 5 h. The solvent was removed under vacuum and the residue obtained was purified by
flash chromatography (AcOEt/petroleum ether = 1/2), which furnished 56 (310 mg,
88%): 1H NMR (CDCl3) δ 8.26 (s, 1H), 6.21 (s, 2H), 1.18 (s, 9H), 0.45 (s, 9H); MS (m/e)
(positive-FAB) 431(M+ + 1).
6-Chloro-2-methylpurin-9-ylmethyl 2,2-Dimethylpropionate (57)
A mixture of tris(dibenzylideneacetone)dipalladium(0) chloroform adduct (Pd2(dba)3, 16
mg, 0.031 mmol), tri o-tolylphosphine (P(o-Tol)3, 31 mg, 0.102 mmol), CuBr (19 mg, 0.135
mmol), and K2CO3 (26 mg, 0.188 mmol) in a flask was dried under reduced pressure, and
the vacuum was replaced by dry nitrogen. A solution of 6-chloro-2-trimethylstannylpurin-9-
ylmethyl 2,2-dimethylpropionate 56 (109 mg, 0.253 mmol) in DMF (2.0 mL) and MeI (0.15
mL, 2.41 mmol) was added, and the mixture was stirred at 60 °C for 3 h. The resulting
reaction mixture was directly pass through a short column (SiO2, 2.0 mL, eluent AcOEt) and
evaporated. The residue obtained was purified by flash chromatography (AcOEt/petroleum
ether = 1/2), which furnished 57 (45 mg, 62%): 1H NMR (CDCl3) δ 8.29 (s, 1H), 6.16 (s,
2H), 2.83 (s, 3H), 1.18 (s, 9H); MS (m/e) (positive-FAB) 283, 285 (peak height ratio 3:1)
(M+ + 1).
6-Methylamino-2-methylpurine (40)
To a solution of 6-chloro-2-methylpurin-9-yl-methyl 2,2-dimethylpropionate 57 (34 mg,
0.120 mmol) in THF (1.0 mL) was added 2.0 N MeNH2 in THF (2.0 mL) and the mixture
stirred for 22 h. The solvent was removed under reduced pressure and the obtained residue
was purified by preparative thin-layer chromatography (first, AcOEt; second, CHCl3/MeOH
= 5/1), which also furnished 6-methylamino-2-methylpurine 40 (27 mg, 81%) and 6-
methylamino-2-methylpurin-9-ylmethyl 2,2-dimethylpropionate (4 mg, 12%): 1H NMR
(DMSO) δ 7.96 (s, 1H), 7.40 (bs, 1H), 2.94 (s, 3H), 2.40 (s, 3H); MS (m/e) (positive-FAB)
164 (M+ + 1).
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1H NMR (DMSO) δ 8.11 (s, 1H), 7.65 (bs, 1H), 6.10 (s, 2H), 2.94 (s, 3H), 2.44 (s, 3H), 1.10
(s, 9H); MS (m/e) (positive-FAB) 278 (M++1).
(1′R,2′S,4′S,5′S)-Phosphoric Acid Di-tert-butyl Ester 1-(Di-tert-
butoxyphosphoryloxymethyl)-4-(2-methyl-6-methylaminopurin-9-yl)bicyclo[3.1.0]hex-2-yl
Ester (47)
To a solution of triphenylphosphine (52 mg, 0.198 mmol) in anhydrous THF (0.40 mL) was
added DEAD (0.030 mL, 0.191 mmol) dropwise at −20 °C with stirring for 1.0 h.
Compound 34 (16.0 mg, 0.030 mmol) and 6-methylamino-2-methylpurine 40 (27 mg,
0.0975 mmol) in THF (1.50 mL) were added to the reaction mixture, which stirred at room
temperature for 3 d. The solvent was removed under vacuum and the residue obtained was
purified by preparative thin-layer chromatography (AcOEt), which furnished 47 (10.0 mg,
49%): 1H NMR (CDCl3) δ 7.99 (s, 1H), 5.62 (br, 1H), 5.38 (m, 1H), 5.09 (d, 1H, J = 6.9
Hz), 4.65 (dd, 1H, J = 4.5, 11.4 Hz), 3.92 (dd, 1H, J = 6.3, 11.4 Hz), 3.22 (s, 3H), 2.60 (s,
3H), 2.40–2.29 (m, 1H), 2.18–2.05 (m, 1H), 1.80 (m, 1H), 1.49 (s, 18H), 1.47 (s, 9H), 1.45
(s, 9H), 1.13–1.08 (m, 1H), 1.01–0.95 (m, 1H).
(1′R,2′S,4′S,5′S)-Phosphoric Acid Di-tert-butyl Ester 1-(Di-tert-
butoxyphosphoryloxymethyl)-4-(2-hexyl-6-methylaminopurin-9-yl)bicyclo[3.1.0]hex-2-yl
Ester (48)
2-Hexynyl bis(di-tert-butyl phosphate) derivative 50 (13 mg, 0.0176 mmol) was dissolved in
methanol (5 mL), and 5% Pd/C (150 mg) was added. The reaction flask was applied to a
vacuum and filled with hydrogen several times. The reaction mixture was stirred for 2 h at
room temperature under a hydrogen balloon. The resulting mixture was filtrated through a
pad of Celite and washed with methanol (5 mL × 3). The residue was purified by preparative
thin-layer chromatography (CHCl3/MeOH = 20/1) to give the desired 2-hexanyl bis(di-tert-
butyl phosphate) derivative 48 (11.5 mg, 88%): 1H NMR (CDCl3) δ 8.02 (s, 1H), 5.62 (bs,
1H, –NH), 5.35 (dd, 1H, J = 7.7, 14.6 Hz), 5.12 (d, 1H, J = 6.9 Hz), 4.64 (dd, 1H, J = 4.4,
11.0 Hz), 3.90 (dd, 1H, J = 6.3, 11.0 Hz), 3.23 (d, 3H, J = 4.9 Hz), 2.81 (dd, 2H, J = 7.7, 8.0
Hz), 2.34 (dd, 1H, J = 7.7, 15.1 Hz), 2.09 (dt, 1H, J = 8.0, 15.7 Hz), 1.23–1.88 (m, 9H),
1.497 (s, 9H), 1.489 (s, 9H), 1.479 (s, 9H), 1.455 (s, 9H), 1.13 (dd, 1H, J = 4.4, 5.8 Hz), 0.98
(dd, 1H, J = 6.3, 8.5 Hz), 0.89 (m, 3H); MS (m/e) (positive-FAB) 744.5 (M+ + 1).
(1′R,2′S,4′S,5′S)-Phosphoric Acid Di-tert-butyl Ester 1-(Di-tert-butoxy-
phosphoryloxymethyl)-4-(2-hex-1-enyl-6-methylaminopurin-9-yl)bicyclo[3.1.0]hex-2-yl
Ester (49)
2-Hexenyl bis(di-tert-butyl phosphate) derivative 49 (6.1 mg, 44%) was prepared by a
method similar to that for 46, except 2-hexenyl-6-methylaminopurine 41 (10 mg, 0.0189
mmol) was used as the starting material: 1H NMR (CDCl3) δ 8.01 (s, 1H), 7.11 (dt, 1H, J =
6.9, 15.4 Hz), 6.48 (dt, 1H, J = 1.4, 15.6 Hz), 5.62 (bq, 1H, –NH), 5.38 (dd, 1H, J = 7.7, 14.3
Hz), 5.14 (d, 1H, J = 6.9 Hz), 4.65 (dd, 1H, J = 4.7, 11.3 Hz), 3.91 (dd, 1H, J = 6.3, 11.3
Hz), 3.24 (d, 3H, J = 5.0 Hz), 2.35 (dd, 1H, J = 8.5, 15.4 Hz), 2.29 (m, 2H), 2.11 (dt, 1H, J =
7.7, 15.4 Hz), 1.80 (dd, 1H, J = 4.1, 8.5 Hz), 1.33–1.61 (m, 4H), 1.496 (s, 9H), 1.490 (s,
9H), 1.482 (s, 9H), 1.446 (s, 9H), 1.13 (dd, 1H, J = 4.4, 5.8 Hz), 0.98 (dd, 1H, J = 6.3, 8.5
Hz), 0.94 (m, 3H); MS (m/e) (positive-FAB) 742.5 (M+ + 1).
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(1′R,2′S,4′S,5′S)-Phosphoric Acid Di-tert-butyl Ester 1-(Di-tert-
butoxyphosphoryloxymethyl)-4-(2-hex-1-ynyl-6-methylaminopurin-9-yl)bicyclo[3.1.0]hex-2-
yl Ester (50)
2-Hexynyl bis(di-tert-butyl phosphate) derivative 50 (20.1 mg, 72%) was prepared by a
method similar to that for 44, except 2-hexynyl-6-methylaminopurine 42 (20 mg, 0.0378
mmol) was used as the starting material: 1H NMR (CDCl3) δ 8.14 (s, 1H), 5.77 (bs, 1H),
5.33 (dd, 1H, J = 8.2, 14.8 Hz), 5.21 (d, 1H, J = 6.9 Hz), 4.67 (dd, 1H, J = 4.4, 11.3 Hz),
3.83 (dd, 1H, J = 6.6, 11.3 Hz), 3.25 (bs, 3H), 2.46 (t, 2H, J = 7.1 Hz), 2.29 (dd, 1H, J = 8.0,
15.4 Hz), 2.08 (m, 1H), 1.60–1.82 (m, 5H), 1.499 (s, 9H), 1.488 (s, 9H), 1.472 (s, 9H), 1.462
(s, 9H), 1.12 (dd, 1H, J = 4.4, 5.8 Hz), 0.9 (m, 1H), 0.94 (t, 3H, J = 7.1 Hz); MS (m/e)
(positive-FAB) 740.5 (M+ + 1).
(1′R,2′S,4′S,5′S)-Phosphoric Acid Di-tert-butyl Ester 1-(Di-tert-butoxy-
phosphoryloxymethyl)-4-(6-chloro-2-trimethylstannylpurin-9-yl)bicyclo[3.1.0]hex-2-yl Ester
(52)
To a solution of 51 (2.7 mg, 0.0034 mmol) and PdCl2-(PPh3)2 (3.5 mg, 0.0050 mmol) in
dioxane (0.30 mL) was added Me3SnSnMe3 (20 mg, 0.061 mmol) and the mixture stirred at
60 °C for 3.5 h. The solvent was removed under vacuum and the residue obtained was
purified by preparative TLC (AcOEt), which furnished 52 (0.7 mg, 25%): 1H NMR (CDCl3)
δ 8.42 (s, 1H), 5.40–5.20 (m, 2H), 4.65 (m, 1H), 3.90 (m, 1H), 2.40–2.25 (m, 1H), 2.25–
2.10 (m, 1H), 1.90–1.80 (m, 1H), 1.50 (s, 9H), 1.48 (s, 18H), 1.44 (s, 9H), 1.25–1.20 (m,
1H), 1.05–1.00 (m, 1H), 0.43 (s, 9H); MS (m/e) (positive-FAB) 827 (M++1), 849 (M++Na).
Small-Scale Conversion of Compound 52 into Compound 12
A 20 µL (0.35 µmol) portion of an iodine solution (4.5 mg of I2 in 1.00 mL of AcOEt) was
added to a solution of 52 (0.15 mg, 0.18 µmol) in AcOEt (0.100 mL) and the mixture stirred
at room temperature for 10 min. Then 0.01 mL of 5% aqueous NaHSO3 was added to stop
the reaction, and the solvent was removed under vacuum. The residue (crude 29) was
dissolved in 5% TFA/CH2Cl2 (0.50 mL) and stirred for 3 h at 25 °C. The solvent was
removed under reduced pressure, and the residue was quenched by addition of 5.0 mL of
triethylammonium bicarbonate buffer (1.0 M). The mixture was subsequently frozen and
lyophilized. The residue (crude 29) was dissolved in 40% MeNH2 in water (0.50 mL) and
stirred for 3 h at room temperature. The solvent was removed under reduced pressure. The
residue (crude 12) was purified by HPLC (system A or system B).
Enzymatic Synthesis of 5
ATP (20 nmol, 2 µL of a 10-mM solution in water) and polynucleotide kinase (Sigma, 10
IU) were added to 20 µL of a buffer consisting of 50 mM Tris HCl, 10 mM MgCl2, 5 mM
dithiothreitol, 0.1 mM spermidine, and 0.1 mM EDTA. The nucleotide substrate 5841 (1 µL
of a 10-mM solution in water) was then added, and the mixture was mixed with vortexing
and incubated at 37 °C for the time indicated (18 h incubation was found to be optimal).
Aliquots (10 µL) were injected for HPLC analysis. A C18 Zorbax column (Agilent) was
used, with the flow rate 1 mL/min and the mobile phase consisting of a gradient of
acetonitrile/0.1 M triethylammonium acetate (aq) of 10/90 to 15/85 in 10 min, then to 30/70
in 10 min. The product of the enzymatic transformation (5) was detected in ~40% yield, as
judged with HPLC. The retention time of the product was 6.2 min, compared with the
starting material, which had a retention time of 8.1 min. These three individual peaks were
collected and lyophilized. Mass spectrometry (FAB) confirmed the identity of the starting
material (m/z 387, M − 1) and product 5 (m/z 468, M − 1). The side product at retention
time 11.6 min displayed an m/z of 310, consistent with the corresponding nucleoside (M +
1). An unidentified impurity present in the starting material was also detected at 7.7 min.
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Compound 58 was found to be chemically stable. The HPLC profile of a solution in H2O/
acetonitrile/buffer was unchanged following 60 h incubation at 37 °C. However, when
enzyme was added in the absence of ATP, ~20% of the compound was dephosphorylated
during an incubation of 17 h to the nucleoside 59 (HPLC retention time = 11.6 min). Under
the same incubation conditions in the presence of the enzyme, 5 was stable.
Pharmacological Analyses
The affinities of 2-substituted (N)-methanocarbo bisphosphate analogues for the human
P2Y1 receptor were directly determined by using [3H]5 in a radioligand binding assay, as we
recently described in detail.31 Briefly, the human P2Y1 receptor was expressed to high
levels in Sf9 insect cells with a recombinant baculovirus. Membranes prepared from these
cells were incubated for 30 min at 4 °C in the presence of ~20 nM [3H]5 and a wide range of
concentrations of the newly synthesized analogues. Binding reactions were terminated by
the addition of ice-cold tris-(hydroxymethyl)aminomethane (Tris) wash buffer (10 mM Tris,
pH 7.5, and 145 mM NaCl) to the samples followed by rapid filtration over GF/A glass-fiber
filters. Each filter was washed with an additional 4 mL of wash buffer, and radioactivity
retained by the filters was quantified by liquid scintillation spectrometry. All assays were
carried out in triplicate, and competition curves for all molecules were generated in three
separate experiments. IC50 values were determined from each competition curve, and a Ki
value was calculated for each analogue according to the relationship Ki = IC50/1 + [[3H]5]/
Kd of [3H]5, where the Kd of [3H]5 determined in separate experiments was 8 nM.
P2Y receptor-promoted stimulation of inositol phosphate formation was measured at human
P2Y1 receptors stably expressed in 1321N1 human astrocytoma cells as previously
described.19,42,43 The K0.5 values were averaged from three to eight independently
determined concentration-effect curves for each compound. Briefly, cells plated in 24-well
dishes were labeled in inositol-free medium (DMEM; Gibco, Gaithersburg, MD) containing
1.0 µCi of 2-[3H]myo-inositol (20 Ci/mmol; American Radiolabeled Chemicals, Inc., St.
Louis, MO) for 18–24 h in a humidified atmosphere of 95% air/5% CO2 at 37 °C.
Phospholipase C activity was measured the following day by quantitating [3H]inositol
phosphate accumulation after a 10-min incubation at 37 °C in the presence of 10 mM LiCl.
Total [3H]inositol phosphates were quantified by anion-exchange chromatography as
previously described.42,43
Data Analysis
IC50 values obtained in radioligand binding assays and in assays of inhibition of 2MeSADP-
stimulated inositol phosphate accumulation were calculated by a four-parameter logistic
equation and the GraphPad software package (GraphPad, San Diego, CA). All
concentration–effect curves were repeated in at least three separate experiments, carried out




We prepared methanocarbocyclic analogues of various bisphosphate derivatives (Table 1) in
which fused cyclopropane and cyclopentane rings were fixed the pseudoribose moiety in a
rigid (N)-envelope conformation. Synthetic intermediates included O-benzyl-protected
phosphoesters, carbocyclic derivatives, adenine derivatives, and O-tert-butyl-protected
phosphoesters (Schemes 1–5). The nucleotide analogues 7–18 were prepared in the
ammonium salt form according to the methods shown in Schemes 1 and 4 and tested
biologically as antagonists at the P2Y1 receptor (Table 1). Identity was confirmed by NMR
Kim et al. Page 16













(1H and 31P) and high-resolution mass spectrometry (HRMS), and purity was demonstrated
with high-performance liquid chromatography (HPLC) in two different solvent systems.
To construct the pseudoribose ring leading to the 2′-deoxy-(N)-methanocarba-2′-
deoxyadenosine precursors, a bicyclo[3.1.0]hexane intermediate 19 was prepared by the
new, optimized approach of Yoshimura et al.,32 which used simple starting materials and
enzymatic transformations. Scheme 1 illustrates the usual synthetic route to the bisphosphate
derivatives, in which the phosphorylation was carried out on the preformed nucleoside
precursor. To prepare that nucleoside, a commercially available 2-substituted adenine
intermediate, 6-chloro-2-aminopurine 20, was condensed with the protected bicyclohexane
derivative 19 via a Mitsunobu reaction to give 21, which was then deprotected to give diol
22. The 3′- and 5′-hydroxyl groups then were phosphorylated by the phosphoramidite
method33 using dibenzyl diisopropyl phosphoramidite 23 to give the benzyl-protected
derivative 24. The 2-amino group of 24 was replaced with an iodo, methylthio, or
methylseleno group (protected intermediates 25–27) with the use of a neutral purinyl radical,
which was generated transiently from the thermal homolysis of the 2-diazonium
intermediate. This was accomplished by using the approach introduced by Nair and
Fasbender34 for the preparation of 2-methylthio and other 2-derivatives of adenosine.
Selenium was selected for inclusion because of its similarity to sulfur and because of its
known use in X-ray crystallography of proteins, when incorporated into ligands as a heavy
atom.35 To introduce an amino or methylamino group at the 6-position, it was necessary to
substitute 6-Cl with the corresponding amine, which could be accomplished either before (to
give 13) or following (to give 7, 8, 12, or 14) deprotection of the phosphate groups. First we
synthesized the N6-methyl-2-methylthio derivative 13, following the procedure in Scheme 1.
However, we were unable to apply this route for the corresponding N6-amino derivative 8
because treatment of 26 with ammonia to replace the 6-chloro group caused side reactions.
Therefore, we carried out an ammonia replacement reaction following deprotection of the
benzyl groups to obtain the N6-amino derivative 8. We used similar procedures of
phosphoester deprotection followed by replacement of the 6-chloro group for the preparation
of the 2-methylseleno derivative 14.
As an alternate synthetic route to the bisphosphate derivatives, phosphate groups were
introduced into a versatile phosporylated bicyclo[3.1.0]hexane precursor 34, protected with
tert-butyl ester groups, prior to the Mitsunobu coupling (Scheme 2).
We first attempted to synthesize 2-fluoro 10 and 2-bromo 11 derivatives by the approach
shown in Scheme 1, which used the phosphoramidite route to phosphorylate the
corresponding nucleoside diol derivative.18 However, only traces of the products were
obtained due to side reactions, which seemed to result from the high nucleophilicity of the 6-
amino group. Thus, an alternate route was needed. For substitution of the 2-position of the
purine ring with bromo or fluoro, the corresponding adenine precursors 37 and 38 were
prepared (Scheme 3). We used 20, a commercially available material, to prepare the
dihaloadenines 35 and 36 by a method from the literature.36 Subsequent methylamination of
the 6-position gave 37 and 38, which were coupled with the methanocarba moiety 34 by a
Mitsunobu reaction. 2-Iodo-N6-methyladenine 39 was prepared with the method of Nair and
Fasbender.34 The two 2-alkene/alkyne-substitituted adenines 41 and 42 were prepared as
previously reported.37 These 2-haloadenine derivatives and several 2-C-substituted
analogues were incorporated into the nucleoside structure as shown in Scheme 4, via the
protected bicyclo[3.1.0]-hexane precursor 34. Following the Mitsunobu reaction, the
hexynyl intermediate 50 was reduced to the corresponding alkane to give 48. Deprotection
of the tert-butyl groups was carried out with TFA to give the bisphosphate derivatives 10–12
and 15–18.
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The preparation of additional 2-substituted adenine intermediates, including 6-chloro-2-
iodopurine 43 used in Scheme 4, required a separate synthetic strategy (Scheme 5). The
adenine precursor 20 dissolved in polar organic solvents, e.g. pyridine or DMSO, only to a
limited extent, which made the selection of transformation conditions difficult. To proceed
further, we applied a protecting group at the N-9 position, expecting an improvement in
solubility. The pivaloyloxymethyl group was chosen as the protecting group, and 54 was
prepared with the method of Rasmussen and Leonard.41 Compound 54 dissolved well in the
usual organic solvents, allowing the 2-iodination of 54 to be performed by the method of
Nair and Fasbender.34
With the success of [3H]5 as a selective radioligand for P2Y1 receptor characterization,31 we
sought to design new antagonists in this series as high-affinity receptor probes. As a route to
a novel iodinated analogue that could be potentially radiolabeled, we explored the
substitution of the iodo group of 12 (Scheme 4) and its adenine precursors (Scheme 5) with
trimethyltin.38,39 This provides a means of rapidly obtaining the iodinated ligand 12. Similar
methodology based on trialkyl tin precursors has been used to prepare radioiodinated ligands
for SPECT (single photon emission computed tomography).39,40 The 2-iodo product 55 was
converted to the 2-trimethylstannyl derivative 56 by the method of Baranowska-Kortylewicz
et al.42 Compound 56 was a useful intermediate because it could serve as a suitable substrate
for Stille coupling; thus, we decided to prepare the 2-methyl derivative. Compound 56
reacted with methyl iodide under the conditions of Suzuki et al.43 The product 57 was
treated with methylamine to make 40, which was coupled with the methanocarba moiety by
a Mitsunobu reaction. Deprotection was carried out with TFA to give the bisphosphate
derivative 15.
As an alternate route to introduce iodine in the antagonist 12, we also attempted stannylation
of 46 with the method of Baranowska-Kortylewicz et al., to be followed by reiodination.42
However, we obtained only the 2-H derivative, which formed upon replacement of the
trimethylstannyl group by hydrogen, which was readily available from an acidic proton such
as the 6-NH(Me). As an alternative (Scheme 4), we tried stannylation using a 6-chloro
derivative 51. This intermediate was synthesized from 43, which was obtained by hydrolysis
of 55, and was coupled with the methanocarba moiety by a Mitsunobu reaction. Intermediate
51 was successfully stannylated with the method of Baranowska-Kortylewicz et al.42 The
trimethyl stannyl derivative 52 reacted with iodine (which could be generated rapidly from
iodide) and re-formed 51. By mass spectral analysis of the iodination reaction at various
time points (1–40 min), an optimal reaction time was determined to be 10 min. Deprotection
of 51 on a small scale with TFA was accomplished to give the bisphosphate derivative 29,
which was then converted to the antagonist 12 (Scheme 1).
We have explored a synthetic methodology that would allow a phosphate group to be
incorporated in a potent P2Y1 receptor antagonist in the final synthetic step. Although
chemical phosphorylation methods were used until now to prepare P2Y1 receptor
antagonists in this series, we devised an enzymatic method for the phosphorylation at the 5′-
position, leading to compound 5. This method (Scheme 6) is based on phosphorylation with
polynucleotide kinase (EC 2.7.1.78).44 The 3′-monophosphorylated intermediate 5845 was
treated with the enzyme and ATP as the phosphate source. Following incubation for 60 min,
the product 5 was detected in ~40% yield, as judged by using HPLC. The intermediate 58
was found to be chemically stable under the incubation conditions. A side reaction, removal
of the 3′-phosphate group of 58 to yield the nucleoside analogue 59, occurred to a
significant degree only in the absence of ATP.
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We recently developed [3H]5 as a high-affinity and selective radioligand for quantification
of the P2Y1 receptor.31 Therefore, the human P2Y1 receptor can be expressed from a
baculovirus to high levels in Sf9 insect cells, and membranes prepared from these cells can
be labeled specifically with [3H]5 to directly assess the affinity of newly synthesized
molecules at the P2Y1 receptor. Therefore, human P2Y1 receptor-expressing membranes
were incubated with 10 nM [3H]5 and a wide range of concentrations of 2-substituted (N)-
methanocarba bisphosphate analogues. As illustrated in Figure 1, all of the bisphosphate
derivatives tested interacted with the P2Y1 receptor, as shown by their capacity to inhibit
[3H]5 binding, and this inhibition occurred with kinetics consistent with interaction by the
law of mass action kinetics at a single site. IC50 values were determined (Table 1) from each
competition curve, and a Ki value was calculated for each analogue according to the
relationship Ki = IC50/1 + [[3H]5]/Kd of [3H]5.
We also tested the functional activities of (N)-methanocarba bisphosphate analogues as
agonists and antagonists at the human P2Y1 receptor stably expressed in 1321N1 human
astrocytoma cells (Table 1). Agonist activity was tested by measuring the capacity of
molecules to increase inositol phosphate accumulation by activating the phospholipase C-
coupled P2Y1 receptor, and antagonist activity at the P2Y1 receptor was assessed by
measuring the capacity of these molecules to inhibit 2-methylthio-adenosine 5′-diphosphate
(2Me-SADP)-stimulated accumulation of inositol phosphates.
None of these 2-substituted molecules exhibited agonist activity in the 1321N1 cell-test
system, but all displayed a capacity to inhibit 2MeSADP-stimulated inositol phosphate
accumulation, with an IC50 value consistent with their Ki values determined in binding
experiments. Within the series of 2-halo analogues, the most potent antagonist in both
functional and binding models was a (N)-methanocarba-2-iodo analogue 12, and all other 2-
halo derivatives were clearly less potent. This derivative displayed a Ki value in competition
for binding of [3H]5 at the hP2Y1 receptor of 0.79 nM. The N6-methyl derivative 12 was 16-
fold more potent in binding than the corresponding 6-amino analogue 7. The corresponding
N6-methyl 2-bromo and 2-chloro derivatives 11 and 5 exhibited similar Ki values and
affinities that were 5–10-fold less than that for 12, and the fluoro derivative 10 exhibited a
much lower affinity (Figure 1). The (N)-methanocarba-2-methylthio-, 2-methylseleno, 2-
hexyl, 2-(1-hexenyl), and 2-(1-hexynyl) analogues exhibited lower affinities than did most
of the 2-halo derivatives, with Ki values in the micromolar range observed for these
compounds at P2Y1 receptors. No significant difference was observed between the alkene
and alkyne derivatives 17 and 18, whereas the corresponding alkane 16 exhibited a 4–5-
fold-lower affinity, with a Ki value in binding calculated to be 80 nM. However, the 2-
methyl derivative 15 was nearly as potent as the corresponding 2-chloro analogue 5.
Schild analysis of antagonism by 12 of inositol phosphate accumulation in 1321N1 human
astrocytoma cells stably expressing the human P2Y1 receptor, stimulated by 2-MeS-ADP,
was carried out (Figure 2). A KB value of 1.74 nM was determined, in close agreement with
binding data for this compound.
A correlation of binding affinities (expressed as Ki values) and functional antagonistic
potencies (expressed as IC50 values) at the human P2Y1 receptor was examined for nine
compounds (Figure 3). The degree of correlation was high, with an r2 value of 0.98. Thus, as
we showed recently in radioligand binding assays with [3H]5 and previously studied
bisphosphate analogues,31 the radioligand binding assay is a readily applicable predictor of
the functional effects of the P2Y1 receptor antagonists.
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In previous studies,18,20 we concluded that substitution of the ribose moiety with the (N)-
methanocarba ring system provides an enhancement of affinity at the P2Y1 receptor. We
strengthened this conclusion in the present study. For example, the compounds homologous
to 8, 12, and 13 were reported in the ribose series,17 and the IC50 values in the same
phospholipase C assay in turkey erythrocytes expressing an endogenous P2Y1 receptor were
1890, 891, and 362 µM, respectively. This is to be compared to the values for 8, 12, and 13
of 367, 8.4, and 221 nM, respectively. Thus, the enhancement achieved upon
conformationally constraining the ribose-like ring in the preferred (N)-conformation was
present in all three cases. However, the degree of enhancement ranged from slight, in the
case of the N6-methyl-2-methylthio analogue 13, to dramatic, i.e., 106-fold, in the case of
the N6-methyl-2-iodo analogue 12.
In the present study, we focused on optimization of the 2-position substitution. Halo
substitution demonstrated a potency order of I > Br, Cl > F, which did not correspond to the
relative effects of these substitutions in the ribose series.17 The 2-alkylthio substitution,
which was found to greatly enhance potency in the agonist series, i.e., 5′-mono-, di-, and
triphosphates,21–23 did not enhance antagonist potency in the present series. This
observation is similar to previous findings with other nucleotide antagonists of the P2Y1
receptor.17 In contrast with C-substitution at the 2-position of adenine reported previously24
(i.e., 2-methyl in the ribose series), we did not find an enhancement of affinity in the alkene
and alkyne analogues synthesized here.
The methods explored in this study for incorporation of iodo and phosphate groups from
simple chemical precursors might be suitable for the preparation of radioligands
(containing 125I, 33P, etc.) of high affinity for the P2Y1 receptor.
In conclusion, we have enhanced the potency of ring-constrained P2Y1 receptor antagonists
by 2-position substitution. The structure–activity relationship (SAR) patterns were not
entirely in parallel to the SAR observed in the ribose series. Thus, subtle differences in the
mode of receptor binding probably occur between ribose-containing and (N)-methanocarba
nucleotides. A key finding in this study is that compound 12 is the most potent antagonist
selective for the P2Y1 receptor yet reported. These findings promise to be useful in defining
the microscopic determinants of the binding sites on these receptors and in designing novel
pharmacological probes, including radioligands, and/or therapeutic agents.
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Inhibition of [3H]5 binding to human P2Y1 receptors by 2-substituted analogues. [3H]5
binding assays were carried out as described in the Experimental Section using Sf9
membranes expressing recombinant human P2Y1 receptor. The data are presented as percent
of total radioligand binding measured in the presence of the indicated concentrations of 2-
chloro (5), 2-fluoro (10), 2-bromo (11), 2-iodo (12), and 2-methylthio (13) N6-methyl
substituted analogues. The data are the mean of triplicate determinations, and the results are
consistent with those obtained in three separate experiments.
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Competitive antagonism of 2MeSADP-promoted activation of the human P2Y1 receptor.
Phospholipase C activity was measured as described in the Experimental Section in 1321N1
human astrocytoma cells stably expressing the human P2Y1 receptor. Top panel: assays
were in the presence of the indicated concentrations of the agonist 2Me-SADP alone or in
the presence of the potent antagonist 12 at 3, 10, 30, 100, and 300 nM. The data are the
means of triplicate determinations and are representative of results obtained in four separate
experiments. Lower panel: Schild analysis of antagonism by 12 of inositol phosphate
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accumulation in 1321N1 human astrocytoma cells stably expressing the human P2Y1
receptor, stimulated by 2-MeS-ADP.
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Correlation of binding affinities at the human P2Y1 receptor expressed in Sf9 cells and
functional potencies as P2Y1 receptor antagonists (measuring inhibition of inositol
phosphate accumulation in 1321N1 human astrocytoma cells stably expressing the human
P2Y1 receptor, stimulated by 30 nM 2-MeS-ADP).
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a Reagents: (i) DIAD, Ph3P, rt, 2-amino-6-chloropurine; (ii) BCl3, CH2Cl2, −40 °C; (iii) 1H-
tetrazole then m-CPBA; (iv) CH2I2, or MeSSMe, or MeSeSeMe, t-BuONO, MeCN; (v)
MeNH2/THF; (vi) BCl3, CH2Cl2, 5 °C; (vii) NH3/H2O, 70 °C, 2 h; (viii) MeNH2/H2O.
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a Reagents: (i) Ac2O, cat. DMAP, TEA, CH2Cl2, rt, 4 h; (ii) wet 5% Pd/C, H2, MeOH, rt, 4
h; (iii) (t-BuO)2PNEt, tetrazole, THF, rt, 1 h then m-CPBA, −78 to 0 °C, 20 min; (iv)
K2CO3, MeOH, rt, 2 h.
Kim et al. Page 29














a Reagents: (i) SbBr3/CH2Br2, t-Bu nitrite; (ii) HF/pyridine, t-Bu nitrite; (iii) CH3NH2/THF
or H2O.
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a Reagents: (i) 2-substituted (iodo, methyl, 2-hexenyl) 6-methylaminopurine or 2-iodo-6-
chloropurine, Ph3P, DEAD, THF, rt, 2 h; (ii) 2-substituted (fluoro, bromo, or 2-hexynyl) 6-
methylaminopurine, Ph3P, DIAD, THF; (iii) 5% Pd/C, H2, MeOH, rt, 2 h; (iv) 5% TFA in
CH2Cl2, rt, 2 h; (v) PdCl2(PPh3)2, Me3SnSnMe3, dioxane, 60 °C; (vi) I2, THF, rt.
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a Reagents: (i) K2CO3, DMSO–DMF, rt, 3 d; (ii) CH2I2, t-BuONO, acetonitrile, 60 °C, 2.5
h; (iii) PdCl2(PPh3)2, Me3SnSnMe3, dioxane, 100 °C, 5 h; (iv) Pd2(dba)3, P(o-tol)3, CuBr,
K2CO3, MeI, DMF, 60 °C, 3 h; (v) CH3NH2/THF, rt, 22 h; (vi) 5N NaOH, i-PrOH, rt, 3 d.
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a Reagents: (i) polynucleotide kinase, ATP; (ii) polynucleotide kinase, alone.
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Table 1
In Vitro Pharmacological Data at Human P2Y1 Receptors for Inhibition of PLC Elicited by 30 nM 2-MeSADP






7 I H 12.6 ± 0.3 87 ± 1
8 SCH3 H 863 ± 400 367 ± 194
9 H CH3 17.6 ± 2.7 157 ± 60
10 F CH3 45 ± 21 356 ± 122
5c Cl CH3 2.5 ± 0.4 52 ± 1
11 Br CH3 5.1 ± 0.6 37 ± 6
12c I CH3 0.78 ± 0.08 8.4 ± 0.8
13 SCH3 CH3 91 ± 12 221 ± 30
14 SeCH3 CH3 35 ± 4 377 ± 154
15 CH3 CH3 3.6 ± 0.7 49 ± 1
16 (CH2)5CH3 CH3 80 ± 10 452 ± 221
17 trans-CH=CH-(CH2)3CH3 CH3 330 ± 70 1870 ± 590
18 C≡C-(CH2)3CH3 CH3 430 ± 200 2400 ± 600
a
The affinities were determined by using [3H]5 in a radioligand binding assay, as recently described.31 The human P2Y1 receptor was expressed
to high levels in Sf9 insect cells with a recombinant baculovirus. Membranes prepared from these cells were incubated for 30 min at 4 °C in the
presence of ~20 nM [3H]5.
b
Antagonist IC50 values (mean ± standard error) represent the concentration needed to inhibit by 50% the effect elicited by 30 nM 2-MeSADP.
The percent of maximal inhibition is equal to 100 minus the residual fraction of stimulation at the highest antagonist concentration. N = 3, unless
otherwise indicated in parentheses.
c
5, MRS 2279; 12, MRS 2500.
d
Mean ± SEM given for three separate determinations. None of the compounds displayed agonist effects. R and R′ are defined in Scheme 1.
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